Apretude is an anti-HIV drug owned by Viiv Healthcare. The active ingredient of the drug is cabotegravir and it was initially authorized for market use on December 20, 2021.
Apretude's generic could be released after September 15, 2031, when the last patent expires. However, drug patent challenges can be filed against it from January 21, 2025, which could potentially lead to an earlier release of a generic version.
Apretude is mainly used for HIV treatment. Its active ingredient, cabotegravir, works by inhibiting the integrase of the HIV virus, preventing it from multiplying and instead allowing the immune system to control the virus.
Apretude holds three patents, with none expired so far. The expiration date of the last patent is September 15, 2031. Details of the Apretude's patents can be found below: